Search Results

higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100

biopsies in a population-based screening study: the impact of borderline lesions . Cancer 1999 ; 85 : 145 – 152 . 35 Orozco R O'Dowd G Kunnel B . Observations on pathology trends in 62,537 prostate biopsies obtained from urology private

Pathology . J Mol Diagn 2006 ; 8 : 412 – 419 . 12. Maxson JE Gotlib J Pollyea DA . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML . N Engl J Med 2013 ; 368 : 1781 – 1790 . 13. Piazza R Valletta S

only medical and radiation oncology, but also thoracic surgery, pathology, and diagnostic radiology. Another substantial improvement in the NCCN Guidelines for SCLC (and many others) has been the inclusion of “Principles of” sections that provide

: 65 – 69 . 15. Morris E Maughan NJ Forman D Quirke P . Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? – The need for high quality pathology . Gut 2007 ; 56 : 1419 – 1425 . 16. Soreide K Janssen EA

hand-offs that occur during the intake and registration processes; obtaining patient materials (pathology tissue, radiology films) with complete interpretation in advance of the patient’s first visit; and wherever possible, performance of studies in

radiation oncology, medical oncology, pathology, radiology, and internal medicine subspecialties, potentially influencing overall survival in a manner that is independent of the institution’s case volume of the particular surgery of interest. Even if we

Pathology” (see BRAIN-F, pages 1334 and 1335) to provide background and recommendations for histologic characterization and molecular testing for gliomas. This article also describes data from clinical trials with available molecular information that have

Neoadjuvant Treatment Following neoadjuvant chemotherapy, indications for RT should be guided by maximal disease stage from either prechemotherapy tumor characteristics at diagnosis or postchemotherapy pathology results. Patients with residual nodal disease

kidney, hydronephrosis, metanephric tumors (ie, adenoma, stromal tumor, adenofibroma), multicystic kidney disease, polycystic kidney disease, renal hemorrhage, and renal vein thrombosis. Pathology To avoid potential tumor spread from malignant